Ginkgo Bioworks Valuation
| DNA Stock | USD 8.97 0.34 3.65% |
At this time, the firm appears to be fairly valued. Ginkgo Bioworks Holdings retains a regular Real Value of $9.16 per share. The prevalent price of the firm is $8.97. Our model calculates the value of Ginkgo Bioworks Holdings from evaluating the firm fundamentals such as Return On Asset of -0.16, return on equity of -0.5, and Current Valuation of 525.1 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ginkgo Bioworks' valuation include:
Price Book 1.0207 | Enterprise Value | Enterprise Value Ebitda (1.79) | Price Sales 3.1233 | Enterprise Value Revenue 2.9477 |
Fairly Valued
Today
Please note that Ginkgo Bioworks' price fluctuation is slightly risky at this time. Calculation of the real value of Ginkgo Bioworks Holdings is based on 3 months time horizon. Increasing Ginkgo Bioworks' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ginkgo Bioworks is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ginkgo Stock. However, Ginkgo Bioworks' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.97 | Real 9.16 | Target 10.0 | Hype 9.08 | Naive 7.62 |
The real value of Ginkgo Stock, also known as its intrinsic value, is the underlying worth of Ginkgo Bioworks Holdings Company, which is reflected in its stock price. It is based on Ginkgo Bioworks' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ginkgo Bioworks' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ginkgo Bioworks Holdings helps investors to forecast how Ginkgo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ginkgo Bioworks more accurately as focusing exclusively on Ginkgo Bioworks' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ginkgo Bioworks' intrinsic value based on its ongoing forecasts of Ginkgo Bioworks' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ginkgo Bioworks' closest peers. If more than one evaluation category is relevant for Ginkgo Bioworks we suggest using both methods to arrive at a better estimate.
Ginkgo Bioworks Cash |
|
Ginkgo Bioworks Total Value Analysis
Ginkgo Bioworks Holdings is currently estimated to have company total value of 525.1 M with market capitalization of 564.09 M, debt of 467.73 M, and cash on hands of 561.57 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Ginkgo Bioworks fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
525.1 M | 564.09 M | 467.73 M | 561.57 M |
Ginkgo Bioworks Investor Information
About 70.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ginkgo Bioworks Holdings recorded a loss per share of 6.18. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 20th of August 2024. Based on the key indicators related to Ginkgo Bioworks' liquidity, profitability, solvency, and operating efficiency, Ginkgo Bioworks Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Ginkgo Bioworks Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ginkgo Bioworks has an asset utilization ratio of 16.48 percent. This suggests that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Ginkgo Bioworks Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Ginkgo Bioworks Profitability Analysis
Based on Ginkgo Bioworks' profitability indicators, Ginkgo Bioworks Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Ginkgo Bioworks' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -60.3 M | Current Value -80.8 M | Quarterly Volatility 353.4 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.57 | 0.75 |
|
|
For Ginkgo Bioworks profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ginkgo Bioworks Holdings to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ginkgo Bioworks utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ginkgo Bioworks's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ginkgo Bioworks over time as well as its relative position and ranking within its peers.
Ginkgo Bioworks Earnings per Share Projection vs Actual
The next projected EPS of Ginkgo Bioworks is estimated to be -1.335 with future projections ranging from a low of -1.335 to a high of -1.335. Ginkgo Bioworks' most recent 12-month trailing earnings per share (EPS TTM) is at -6.18. Please be aware that the consensus of earnings estimates for Ginkgo Bioworks Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Ginkgo Bioworks Earnings Estimation Breakdown
The calculation of Ginkgo Bioworks' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Ginkgo Bioworks is estimated to be -1.335 with the future projection ranging from a low of -1.335 to a high of -1.335. Please be aware that this consensus of annual earnings estimates for Ginkgo Bioworks Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.33 Lowest | Expected EPS | -1.33 Highest |
Ginkgo Bioworks Earnings Projection Consensus
Suppose the current estimates of Ginkgo Bioworks' value are higher than the current market price of the Ginkgo Bioworks stock. In this case, investors may conclude that Ginkgo Bioworks is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Ginkgo Bioworks' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 49.62% | -1.45 | -1.335 | -6.18 |
Ginkgo Bioworks Ownership Allocation
Ginkgo Bioworks Holdings has a total of 48.52 Million outstanding shares. Over half of Ginkgo Bioworks' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Ginkgo Bioworks Profitability Analysis
The company reported the last year's revenue of 227.04 M. Reported Net Loss for the year was (547.03 M) with profit before taxes, overhead, and interest of 131.31 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ginkgo Bioworks' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ginkgo Bioworks and how it compares across the competition.
About Ginkgo Bioworks Valuation
The stock valuation mechanism determines Ginkgo Bioworks' current worth on a weekly basis. Our valuation model uses a comparative analysis of Ginkgo Bioworks. We calculate exposure to Ginkgo Bioworks's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ginkgo Bioworks's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 216.8 M | 175.8 M | |
| Pretax Profit Margin | (2.77) | (2.91) | |
| Operating Profit Margin | (2.84) | (2.98) | |
| Net Loss | (2.77) | (2.91) | |
| Gross Profit Margin | 0.75 | 0.57 |
Ginkgo Bioworks Current Valuation Indicators
Valuation refers to the process of determining the present value of Ginkgo Bioworks Holdings and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ginkgo we look at many different elements of the entity such as Ginkgo's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ginkgo Bioworks, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ginkgo Bioworks' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ginkgo Bioworks' worth.Complementary Tools for Ginkgo Stock analysis
When running Ginkgo Bioworks' price analysis, check to measure Ginkgo Bioworks' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ginkgo Bioworks is operating at the current time. Most of Ginkgo Bioworks' value examination focuses on studying past and present price action to predict the probability of Ginkgo Bioworks' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ginkgo Bioworks' price. Additionally, you may evaluate how the addition of Ginkgo Bioworks to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |